| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 61 | 2024 | 1315 | 5.370 |
Why?
|
| Cognition Disorders | 30 | 2015 | 690 | 3.350 |
Why?
|
| Cognitive Dysfunction | 29 | 2023 | 737 | 3.110 |
Why?
|
| Stroke | 18 | 2023 | 241 | 2.760 |
Why?
|
| Diet, Mediterranean | 9 | 2023 | 63 | 1.990 |
Why?
|
| Aged | 90 | 2024 | 7435 | 1.600 |
Why?
|
| Cognition | 30 | 2024 | 947 | 1.510 |
Why?
|
| Humans | 127 | 2024 | 22903 | 1.490 |
Why?
|
| Female | 90 | 2024 | 12934 | 1.390 |
Why?
|
| Brain | 21 | 2024 | 1203 | 1.350 |
Why?
|
| Male | 88 | 2024 | 12453 | 1.330 |
Why?
|
| Aging | 15 | 2021 | 1100 | 1.250 |
Why?
|
| Dementia | 11 | 2023 | 387 | 1.220 |
Why?
|
| Aged, 80 and over | 52 | 2024 | 3720 | 1.180 |
Why?
|
| Biomarkers | 11 | 2023 | 473 | 1.060 |
Why?
|
| Chicago | 22 | 2021 | 813 | 0.970 |
Why?
|
| Stress, Psychological | 4 | 2016 | 207 | 0.900 |
Why?
|
| Neuropsychological Tests | 22 | 2021 | 864 | 0.870 |
Why?
|
| Depression | 4 | 2022 | 368 | 0.840 |
Why?
|
| Longitudinal Studies | 30 | 2021 | 1044 | 0.780 |
Why?
|
| Ischemic Attack, Transient | 1 | 2023 | 16 | 0.770 |
Why?
|
| Amyloid beta-Peptides | 8 | 2024 | 198 | 0.760 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2022 | 856 | 0.760 |
Why?
|
| Risk Factors | 33 | 2023 | 1971 | 0.750 |
Why?
|
| Diet, Western | 1 | 2022 | 6 | 0.740 |
Why?
|
| Attitude | 1 | 2022 | 31 | 0.730 |
Why?
|
| Cardiology | 1 | 2022 | 45 | 0.700 |
Why?
|
| Prospective Studies | 13 | 2023 | 1493 | 0.700 |
Why?
|
| Disease Progression | 14 | 2023 | 525 | 0.690 |
Why?
|
| Community Participation | 1 | 2020 | 13 | 0.660 |
Why?
|
| Apolipoproteins E | 12 | 2023 | 142 | 0.650 |
Why?
|
| Hypertension | 6 | 2022 | 163 | 0.620 |
Why?
|
| Cohort Studies | 21 | 2024 | 1414 | 0.610 |
Why?
|
| tau Proteins | 6 | 2023 | 145 | 0.580 |
Why?
|
| Brain Concussion | 3 | 2023 | 8 | 0.560 |
Why?
|
| Football | 3 | 2023 | 20 | 0.560 |
Why?
|
| Apolipoprotein E4 | 11 | 2021 | 172 | 0.550 |
Why?
|
| Cerebrovascular Disorders | 4 | 2015 | 99 | 0.540 |
Why?
|
| Incidence | 16 | 2023 | 624 | 0.530 |
Why?
|
| Sex Characteristics | 4 | 2023 | 85 | 0.530 |
Why?
|
| Independent Living | 5 | 2023 | 225 | 0.530 |
Why?
|
| Nerve Fibers, Myelinated | 3 | 2013 | 24 | 0.520 |
Why?
|
| Dietary Approaches To Stop Hypertension | 4 | 2021 | 23 | 0.520 |
Why?
|
| Cardiovascular Diseases | 5 | 2019 | 289 | 0.470 |
Why?
|
| Middle Aged | 23 | 2023 | 7911 | 0.440 |
Why?
|
| Diet | 6 | 2022 | 178 | 0.440 |
Why?
|
| Cross-Sectional Studies | 12 | 2022 | 761 | 0.440 |
Why?
|
| Cerebral Infarction | 2 | 2013 | 109 | 0.430 |
Why?
|
| Sex Factors | 8 | 2023 | 387 | 0.380 |
Why?
|
| Brain Infarction | 3 | 2023 | 63 | 0.380 |
Why?
|
| Dietary Supplements | 5 | 2022 | 53 | 0.360 |
Why?
|
| Leukoencephalopathies | 1 | 2011 | 11 | 0.350 |
Why?
|
| Diet Surveys | 3 | 2022 | 22 | 0.340 |
Why?
|
| Vitamin B 12 | 2 | 2011 | 13 | 0.340 |
Why?
|
| Ambulatory Care Facilities | 3 | 2022 | 34 | 0.340 |
Why?
|
| Dementia, Vascular | 3 | 2007 | 36 | 0.330 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2021 | 262 | 0.330 |
Why?
|
| Neuroimaging | 4 | 2021 | 100 | 0.320 |
Why?
|
| Neurodegenerative Diseases | 3 | 2023 | 96 | 0.320 |
Why?
|
| Smoking | 3 | 2012 | 161 | 0.320 |
Why?
|
| Positron-Emission Tomography | 3 | 2023 | 72 | 0.320 |
Why?
|
| Healthy Lifestyle | 4 | 2024 | 36 | 0.310 |
Why?
|
| White Matter | 3 | 2022 | 107 | 0.300 |
Why?
|
| Risk Assessment | 10 | 2022 | 547 | 0.300 |
Why?
|
| Follow-Up Studies | 12 | 2021 | 1409 | 0.290 |
Why?
|
| Atrial Fibrillation | 2 | 2022 | 98 | 0.290 |
Why?
|
| Genome-Wide Association Study | 4 | 2020 | 152 | 0.290 |
Why?
|
| Comorbidity | 8 | 2021 | 426 | 0.280 |
Why?
|
| Memory Disorders | 4 | 2019 | 107 | 0.280 |
Why?
|
| Cerebral Arteries | 2 | 2007 | 21 | 0.270 |
Why?
|
| Time Factors | 6 | 2021 | 1257 | 0.270 |
Why?
|
| Women's Health | 2 | 2019 | 174 | 0.270 |
Why?
|
| Parkinsonian Disorders | 3 | 2022 | 164 | 0.260 |
Why?
|
| Surveys and Questionnaires | 6 | 2022 | 1021 | 0.260 |
Why?
|
| Population Surveillance | 2 | 2021 | 102 | 0.260 |
Why?
|
| Parkinson Disease | 4 | 2022 | 591 | 0.250 |
Why?
|
| Vitamin B 6 | 1 | 2006 | 4 | 0.250 |
Why?
|
| Folic Acid | 1 | 2006 | 21 | 0.250 |
Why?
|
| Patient Selection | 2 | 2021 | 167 | 0.250 |
Why?
|
| Movement Disorders | 1 | 2006 | 57 | 0.240 |
Why?
|
| Urban Health | 1 | 2006 | 18 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2021 | 168 | 0.240 |
Why?
|
| Vitamin D | 2 | 2022 | 27 | 0.230 |
Why?
|
| Proportional Hazards Models | 6 | 2015 | 273 | 0.230 |
Why?
|
| United States | 10 | 2022 | 1765 | 0.220 |
Why?
|
| Niacin | 1 | 2004 | 3 | 0.220 |
Why?
|
| Hypolipidemic Agents | 1 | 2004 | 23 | 0.210 |
Why?
|
| Overweight | 2 | 2022 | 66 | 0.210 |
Why?
|
| Exercise | 4 | 2022 | 392 | 0.210 |
Why?
|
| Early Diagnosis | 2 | 2020 | 50 | 0.200 |
Why?
|
| Risk | 5 | 2015 | 162 | 0.200 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2022 | 147 | 0.200 |
Why?
|
| Day Care, Medical | 3 | 2008 | 6 | 0.190 |
Why?
|
| Emergency Medical Services | 2 | 2020 | 29 | 0.190 |
Why?
|
| Life Style | 5 | 2023 | 159 | 0.190 |
Why?
|
| Gender Identity | 2 | 2023 | 20 | 0.190 |
Why?
|
| Causality | 4 | 2011 | 43 | 0.190 |
Why?
|
| Genetic Loci | 3 | 2020 | 27 | 0.180 |
Why?
|
| Crime Victims | 1 | 2022 | 23 | 0.180 |
Why?
|
| Food | 1 | 2022 | 30 | 0.180 |
Why?
|
| Genetic Testing | 1 | 2022 | 46 | 0.180 |
Why?
|
| Health Status Disparities | 2 | 2019 | 63 | 0.180 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 71 | 0.180 |
Why?
|
| Lutein | 1 | 2021 | 3 | 0.180 |
Why?
|
| Zeaxanthins | 1 | 2021 | 3 | 0.180 |
Why?
|
| Carotenoids | 1 | 2021 | 14 | 0.180 |
Why?
|
| Age Factors | 8 | 2019 | 636 | 0.180 |
Why?
|
| Logistic Models | 6 | 2011 | 350 | 0.170 |
Why?
|
| Prevalence | 5 | 2021 | 376 | 0.170 |
Why?
|
| Clergy | 3 | 2006 | 72 | 0.170 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2020 | 10 | 0.170 |
Why?
|
| Membrane Proteins | 1 | 2021 | 140 | 0.160 |
Why?
|
| Neurofilament Proteins | 1 | 2020 | 16 | 0.160 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2020 | 38 | 0.160 |
Why?
|
| Program Development | 1 | 2020 | 44 | 0.160 |
Why?
|
| Vertigo | 1 | 2000 | 6 | 0.160 |
Why?
|
| Disability Evaluation | 2 | 2007 | 218 | 0.160 |
Why?
|
| Genotype | 4 | 2016 | 248 | 0.160 |
Why?
|
| Advance Care Planning | 1 | 2020 | 10 | 0.160 |
Why?
|
| Endothelium | 1 | 2020 | 13 | 0.160 |
Why?
|
| Terminal Care | 1 | 2020 | 22 | 0.160 |
Why?
|
| Vascular Diseases | 1 | 2020 | 34 | 0.160 |
Why?
|
| Age Distribution | 3 | 2011 | 67 | 0.150 |
Why?
|
| Interviews as Topic | 2 | 2015 | 109 | 0.150 |
Why?
|
| Heart Failure, Diastolic | 1 | 2018 | 3 | 0.150 |
Why?
|
| Cardiovascular Agents | 1 | 2018 | 22 | 0.140 |
Why?
|
| Women's Health Services | 1 | 2018 | 6 | 0.140 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2018 | 17 | 0.140 |
Why?
|
| Patient Care Management | 1 | 2018 | 16 | 0.140 |
Why?
|
| Adult | 10 | 2023 | 6921 | 0.140 |
Why?
|
| Multiple Sclerosis | 2 | 2010 | 77 | 0.140 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 18 | 0.140 |
Why?
|
| American Heart Association | 1 | 2018 | 15 | 0.140 |
Why?
|
| Culturally Competent Care | 1 | 2018 | 8 | 0.140 |
Why?
|
| Mortality | 2 | 2016 | 73 | 0.140 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 19 | 0.140 |
Why?
|
| Linear Models | 3 | 2015 | 192 | 0.140 |
Why?
|
| Atherosclerosis | 1 | 2018 | 44 | 0.130 |
Why?
|
| Amyloid | 3 | 2022 | 37 | 0.130 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2018 | 41 | 0.130 |
Why?
|
| Public Health | 1 | 2018 | 47 | 0.130 |
Why?
|
| Emergency Medical Service Communication Systems | 1 | 2017 | 1 | 0.130 |
Why?
|
| Self Report | 2 | 2022 | 194 | 0.130 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 58 | 0.130 |
Why?
|
| Cognitive Aging | 1 | 2018 | 56 | 0.130 |
Why?
|
| Education | 3 | 2006 | 31 | 0.130 |
Why?
|
| Sex Distribution | 2 | 2011 | 64 | 0.130 |
Why?
|
| Homes for the Aged | 2 | 2007 | 7 | 0.130 |
Why?
|
| Health Promotion | 1 | 2018 | 123 | 0.120 |
Why?
|
| Communication | 1 | 2017 | 96 | 0.120 |
Why?
|
| Nursing Homes | 2 | 2007 | 41 | 0.120 |
Why?
|
| Lipoprotein(a) | 1 | 2016 | 5 | 0.120 |
Why?
|
| Survival Analysis | 2 | 2015 | 226 | 0.120 |
Why?
|
| Dyslipidemias | 1 | 2016 | 15 | 0.120 |
Why?
|
| Odds Ratio | 3 | 2011 | 219 | 0.120 |
Why?
|
| Residence Characteristics | 3 | 2011 | 171 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 31 | 0.110 |
Why?
|
| Psychological Tests | 1 | 2015 | 42 | 0.110 |
Why?
|
| Models, Genetic | 1 | 2015 | 31 | 0.110 |
Why?
|
| Interpersonal Relations | 2 | 2015 | 86 | 0.110 |
Why?
|
| Tissue Donors | 2 | 2012 | 64 | 0.110 |
Why?
|
| Heart Failure | 3 | 2022 | 141 | 0.110 |
Why?
|
| Bias | 2 | 2012 | 23 | 0.110 |
Why?
|
| Prognosis | 4 | 2019 | 728 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2015 | 145 | 0.100 |
Why?
|
| Antioxidants | 2 | 2005 | 56 | 0.100 |
Why?
|
| Memory | 3 | 2006 | 211 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2015 | 267 | 0.100 |
Why?
|
| Alleles | 4 | 2021 | 165 | 0.100 |
Why?
|
| Intermediate Filaments | 2 | 2023 | 19 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2021 | 2985 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 435 | 0.090 |
Why?
|
| Patient Dropouts | 1 | 2012 | 24 | 0.090 |
Why?
|
| Social Support | 1 | 2012 | 174 | 0.090 |
Why?
|
| Community Health Services | 2 | 2009 | 27 | 0.090 |
Why?
|
| Psychometrics | 2 | 2010 | 176 | 0.090 |
Why?
|
| Blood Pressure | 2 | 2022 | 166 | 0.090 |
Why?
|
| Severity of Illness Index | 4 | 2009 | 801 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 2 | 2010 | 60 | 0.080 |
Why?
|
| Neocortex | 1 | 2010 | 22 | 0.080 |
Why?
|
| Confidence Intervals | 3 | 2005 | 74 | 0.080 |
Why?
|
| Decision Support Techniques | 2 | 2010 | 39 | 0.080 |
Why?
|
| Qualitative Research | 2 | 2023 | 92 | 0.080 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2010 | 4 | 0.080 |
Why?
|
| Gene Frequency | 1 | 2010 | 41 | 0.080 |
Why?
|
| Interleukin-7 | 1 | 2010 | 13 | 0.080 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 106 | 0.080 |
Why?
|
| Lewy Body Disease | 1 | 2010 | 70 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2009 | 3 | 0.080 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2009 | 3 | 0.080 |
Why?
|
| Interferon Regulatory Factors | 1 | 2009 | 2 | 0.080 |
Why?
|
| Brain Mapping | 1 | 2010 | 123 | 0.080 |
Why?
|
| Coronary Artery Disease | 2 | 2022 | 124 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2009 | 49 | 0.070 |
Why?
|
| Geriatric Assessment | 3 | 2021 | 158 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2007 | 311 | 0.070 |
Why?
|
| Community Health Nursing | 1 | 2008 | 5 | 0.070 |
Why?
|
| Home Care Services | 1 | 2008 | 21 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2010 | 387 | 0.070 |
Why?
|
| Vitamin E | 2 | 2005 | 37 | 0.070 |
Why?
|
| Isometric Contraction | 1 | 2007 | 8 | 0.070 |
Why?
|
| Lower Extremity | 1 | 2007 | 33 | 0.070 |
Why?
|
| Life Expectancy | 2 | 2022 | 21 | 0.060 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2007 | 12 | 0.060 |
Why?
|
| Quality of Life | 2 | 2022 | 557 | 0.060 |
Why?
|
| Muscle Strength | 1 | 2007 | 99 | 0.060 |
Why?
|
| Case-Control Studies | 3 | 2015 | 479 | 0.060 |
Why?
|
| Research Design | 2 | 2021 | 157 | 0.060 |
Why?
|
| Postural Balance | 1 | 2007 | 103 | 0.060 |
Why?
|
| Mental Disorders | 1 | 2007 | 134 | 0.060 |
Why?
|
| Patient Admission | 1 | 2005 | 18 | 0.060 |
Why?
|
| Hallucinations | 1 | 2005 | 38 | 0.060 |
Why?
|
| Tocopherols | 1 | 2005 | 8 | 0.060 |
Why?
|
| Socioeconomic Factors | 3 | 2010 | 257 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2004 | 51 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 148 | 0.050 |
Why?
|
| Gait | 1 | 2007 | 381 | 0.050 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2023 | 7 | 0.050 |
Why?
|
| Seafood | 1 | 2003 | 8 | 0.050 |
Why?
|
| Caloric Restriction | 1 | 2023 | 11 | 0.050 |
Why?
|
| Urban Population | 2 | 2003 | 127 | 0.050 |
Why?
|
| Activities of Daily Living | 2 | 2007 | 356 | 0.050 |
Why?
|
| Dietary Fats | 1 | 2003 | 37 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 286 | 0.050 |
Why?
|
| Diet, Vegetarian | 1 | 2022 | 5 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 14 | 0.050 |
Why?
|
| Fraud | 1 | 2022 | 16 | 0.050 |
Why?
|
| Motivation | 1 | 2023 | 82 | 0.050 |
Why?
|
| Polypharmacy | 1 | 2022 | 4 | 0.050 |
Why?
|
| Vitamin K | 1 | 2022 | 5 | 0.050 |
Why?
|
| Anthocyanins | 1 | 2022 | 5 | 0.050 |
Why?
|
| Fruit | 1 | 2022 | 24 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2022 | 22 | 0.040 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2022 | 27 | 0.040 |
Why?
|
| Frailty | 1 | 2022 | 22 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2022 | 48 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2022 | 34 | 0.040 |
Why?
|
| Atrial Appendage | 1 | 2022 | 26 | 0.040 |
Why?
|
| Vegetables | 1 | 2021 | 21 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 106 | 0.040 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2001 | 4 | 0.040 |
Why?
|
| Survivors | 1 | 2022 | 69 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2022 | 65 | 0.040 |
Why?
|
| Neurofibrillary Tangles | 1 | 2022 | 117 | 0.040 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2022 | 52 | 0.040 |
Why?
|
| Athletes | 1 | 2021 | 52 | 0.040 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2001 | 39 | 0.040 |
Why?
|
| Probability | 1 | 2021 | 71 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 1651 | 0.040 |
Why?
|
| Accelerometry | 1 | 2021 | 78 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 82 | 0.040 |
Why?
|
| Tremor | 1 | 2022 | 93 | 0.040 |
Why?
|
| Executive Function | 1 | 2021 | 89 | 0.040 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2020 | 5 | 0.040 |
Why?
|
| Weight Loss | 1 | 2022 | 121 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2020 | 24 | 0.040 |
Why?
|
| Self-Assessment | 1 | 2020 | 19 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2018 | 2939 | 0.040 |
Why?
|
| Accidental Falls | 1 | 2022 | 105 | 0.040 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2020 | 47 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2001 | 125 | 0.040 |
Why?
|
| Illinois | 1 | 2021 | 221 | 0.040 |
Why?
|
| Educational Status | 3 | 2007 | 209 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 129 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 2020 | 27 | 0.040 |
Why?
|
| Autopsy | 1 | 2021 | 255 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 2020 | 124 | 0.040 |
Why?
|
| Cardiovascular System | 1 | 2019 | 11 | 0.040 |
Why?
|
| Animals | 2 | 2018 | 3269 | 0.040 |
Why?
|
| Nutrition Assessment | 3 | 2005 | 39 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 234 | 0.040 |
Why?
|
| Survival Rate | 2 | 2011 | 318 | 0.040 |
Why?
|
| Hippocampus | 1 | 2020 | 194 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 210 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 286 | 0.040 |
Why?
|
| Epidemiologic Studies | 2 | 2012 | 17 | 0.040 |
Why?
|
| Asia, Western | 1 | 2018 | 2 | 0.040 |
Why?
|
| Indian Ocean Islands | 1 | 2018 | 2 | 0.040 |
Why?
|
| Cultural Characteristics | 1 | 2018 | 19 | 0.030 |
Why?
|
| Focus Groups | 1 | 2018 | 79 | 0.030 |
Why?
|
| Caregivers | 1 | 2020 | 186 | 0.030 |
Why?
|
| Pregnancy | 1 | 2018 | 324 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2020 | 173 | 0.030 |
Why?
|
| Ambulances | 1 | 2017 | 1 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 137 | 0.030 |
Why?
|
| Models, Statistical | 2 | 2012 | 113 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2018 | 139 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 200 | 0.030 |
Why?
|
| Oncogene Protein v-akt | 1 | 2016 | 8 | 0.030 |
Why?
|
| Registries | 1 | 2018 | 173 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2007 | 84 | 0.030 |
Why?
|
| Mental Status Schedule | 2 | 2007 | 65 | 0.030 |
Why?
|
| Neurologic Examination | 2 | 2007 | 80 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 40 | 0.030 |
Why?
|
| Georgia | 1 | 2016 | 12 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 29 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 260 | 0.030 |
Why?
|
| Diagnosis | 1 | 2015 | 16 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 143 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2015 | 6 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 23 | 0.030 |
Why?
|
| Lewy Bodies | 1 | 2015 | 146 | 0.030 |
Why?
|
| Medicare | 1 | 2014 | 106 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 308 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 526 | 0.020 |
Why?
|
| Markov Chains | 1 | 2012 | 30 | 0.020 |
Why?
|
| Fumarates | 1 | 2011 | 2 | 0.020 |
Why?
|
| Maleates | 1 | 2011 | 2 | 0.020 |
Why?
|
| Phenanthrolines | 1 | 2010 | 2 | 0.020 |
Why?
|
| Carbon Radioisotopes | 1 | 2010 | 4 | 0.020 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2010 | 3 | 0.020 |
Why?
|
| Thiazoles | 1 | 2010 | 15 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 49 | 0.020 |
Why?
|
| Aniline Compounds | 1 | 2010 | 29 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2010 | 69 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 54 | 0.020 |
Why?
|
| Nursing Administration Research | 1 | 2008 | 1 | 0.020 |
Why?
|
| Nursing Assessment | 1 | 2008 | 20 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2008 | 37 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2008 | 58 | 0.020 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2007 | 27 | 0.020 |
Why?
|
| Spatial Behavior | 1 | 2006 | 5 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2007 | 117 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2006 | 36 | 0.020 |
Why?
|
| Patient Transfer | 1 | 2005 | 24 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 1 | 2005 | 36 | 0.010 |
Why?
|
| Psychotic Disorders | 1 | 2005 | 29 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 96 | 0.010 |
Why?
|
| Antipsychotic Agents | 1 | 2005 | 50 | 0.010 |
Why?
|
| gamma-Tocopherol | 1 | 2005 | 7 | 0.010 |
Why?
|
| alpha-Tocopherol | 1 | 2005 | 11 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 234 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 442 | 0.010 |
Why?
|
| Adolescent | 1 | 2010 | 1880 | 0.010 |
Why?
|
| Models, Psychological | 1 | 2004 | 58 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 590 | 0.010 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2003 | 5 | 0.010 |
Why?
|
| Docosahexaenoic Acids | 1 | 2003 | 7 | 0.010 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2003 | 10 | 0.010 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2003 | 14 | 0.010 |
Why?
|
| Population | 1 | 2002 | 3 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2002 | 23 | 0.010 |
Why?
|
| Occupations | 1 | 2002 | 13 | 0.010 |
Why?
|
| beta Carotene | 1 | 2002 | 12 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2002 | 38 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 2002 | 31 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2002 | 83 | 0.010 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2001 | 28 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2001 | 92 | 0.010 |
Why?
|